1. Home
  2. SPNT vs LQDA Comparison

SPNT vs LQDA Comparison

Compare SPNT & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPNT
  • LQDA
  • Stock Information
  • Founded
  • SPNT 2011
  • LQDA 2004
  • Country
  • SPNT Bermuda
  • LQDA United States
  • Employees
  • SPNT N/A
  • LQDA N/A
  • Industry
  • SPNT Property-Casualty Insurers
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SPNT Finance
  • LQDA Health Care
  • Exchange
  • SPNT Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • SPNT 2.1B
  • LQDA 2.5B
  • IPO Year
  • SPNT N/A
  • LQDA 2018
  • Fundamental
  • Price
  • SPNT $18.92
  • LQDA $25.67
  • Analyst Decision
  • SPNT Buy
  • LQDA Strong Buy
  • Analyst Count
  • SPNT 3
  • LQDA 9
  • Target Price
  • SPNT $24.00
  • LQDA $32.11
  • AVG Volume (30 Days)
  • SPNT 929.7K
  • LQDA 2.4M
  • Earning Date
  • SPNT 10-30-2025
  • LQDA 08-12-2025
  • Dividend Yield
  • SPNT N/A
  • LQDA N/A
  • EPS Growth
  • SPNT N/A
  • LQDA N/A
  • EPS
  • SPNT 0.75
  • LQDA N/A
  • Revenue
  • SPNT $2,793,700,000.00
  • LQDA $19,322,000.00
  • Revenue This Year
  • SPNT N/A
  • LQDA $362.31
  • Revenue Next Year
  • SPNT $6.45
  • LQDA $418.29
  • P/E Ratio
  • SPNT $25.18
  • LQDA N/A
  • Revenue Growth
  • SPNT 3.57
  • LQDA 30.20
  • 52 Week Low
  • SPNT $12.78
  • LQDA $9.30
  • 52 Week High
  • SPNT $21.03
  • LQDA $29.94
  • Technical
  • Relative Strength Index (RSI)
  • SPNT 54.69
  • LQDA 50.57
  • Support Level
  • SPNT $18.50
  • LQDA $27.15
  • Resistance Level
  • SPNT $19.15
  • LQDA $29.43
  • Average True Range (ATR)
  • SPNT 0.44
  • LQDA 1.23
  • MACD
  • SPNT 0.07
  • LQDA -0.60
  • Stochastic Oscillator
  • SPNT 67.37
  • LQDA 0.95

About SPNT SiriusPoint Ltd.

SiriusPoint Ltd provides property and casualty reinsurance coverage to insurance and reinsurance companies in the United States, Canada, Bermuda, the United Kingdom, and Europe. The company operates through two operating segments: Reinsurance and Insurance & Services. The company's product portfolio consists of reinsurance contracts for property insurance including both residential and commercial properties, workers' compensation, personal automobile, businesses' general liability insurance, professional liability insurance to protect professional advisors and service providers, agriculture insurance, and mortgage insurance. The majority of the revenue is generated from its Insurance & Services segment.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: